TCRx Therapeutics is the lead sponsor of 8 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are KXV01 TCR Lentinvivo, KSH01 and KSV01. The most-studied condition is Advanced Solid Tumors.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
NCT07596693 · Advanced Solid Tumors
Drug: KXV01 TCR Lentinvivo |
Phase 1 | Recruiting | 2025-12 | China |
|
KSH01-R02-101 Solid Tumors
NCT05580796 · ClinicalTrials.gov ↗ · Solid Tumor
Drug: KSH01 |
Phase EARLY_PHASE1 | Recruiting | 2022-10 | China |
|
KSX01-TCRT Injection Project in Solid Tumors
NCT05811975 · ClinicalTrials.gov ↗ · TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
|
Phase EARLY_PHASE1 | Recruiting | 2023-03 | China |
|
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07260812 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Drug: KSV01 |
Phase 1 | Recruiting | 2025-09 | China |
|
Apheresis Collection for New Drug Development and Evaluation Research
NCT07663565 · ClinicalTrials.gov ↗ · PBMCs
|
Observational | Recruiting | 2026-06 | China |
|
KSH01-TCRT Solid Tumors
NCT05539833 · ClinicalTrials.gov ↗ · TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
Drug: KSH01 |
Phase EARLY_PHASE1 | Recruiting | 2022-08 | China |
|
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
NCT07275853 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: KXV01 TCR Lentinvivo |
Phase 1 | Not yet open | 2025-12 | China |
|
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
NCT07196579 · ClinicalTrials.gov ↗ · Advanced Solid Cancer
Drug: KXV01 TCR Lentinvivo |
Phase 1 | Not yet open | 2025-10 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 8 | 6 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
TCRx Therapeutics is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 3 drugs and biologicals as interventions. The most frequent are KXV01 TCR Lentinvivo (3), KSH01 (2) and KSV01 (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.